CliffBio
biologic

Ocrevus

ocrelizumab

Loss of exclusivityMarch 2029projected — 12-year biologic exclusivity estimate
CompanyGenentech →View the full company profile on CliffBio

Drug detail

Brand nameOcrevus
Active ingredientocrelizumab
Strength300MG/10ML (30MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2017
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Ocrevus patent cliff — loss of exclusivity March 2029 | CliffBio